EFFECTIVENESS AND SAFETY OF ANTI-CGRP MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION IN REAL-WORLD PRACTICE: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5396Keywords:
Anti-CGRP Monoclonal Antibodies, Cardiovascular Safety, Prophylaxis, Medication Overuse Headache, Migraine, Real-World EvidenceAbstract
The transition from Phase III trials to real-world evidence (RWE) is critical for understanding monoclonal antibody (mAb) performance in complex, comorbid populations. This review evaluates the real-world effectiveness and safety of calcitonin gene-related peptide (CGRP) pathway inhibitors in routine clinical practice.
A systematic search of PubMed (2021–2026) identified observational studies, including prospective registries (e.g., PEARL, GARLIT, MAB-MIG) and large-scale claims analyses, regarding erenumab, fremanezumab, galcanezumab, and eptinezumab.
Synthesis of 32 studies (n > 1 million patients) demonstrates robust effectiveness across diverse populations. Real-world data confirm sustained ≥ 50% responder rates (ranging from 40%–75% in most cohorts) and significant reductions in acute medication use. Benefits were maintained over 12–36 months, even in patients with chronic migraine and medication overuse headaches. Large-scale analyses (MarketScan, Medicare) indicate that CGRP inhibitors are not associated with an increased risk of myocardial infarction or stroke compared to onabotulinumtoxinA, even in older adults. Switching between ligand and receptor targets remains an effective strategy for initial non-responders.
RWE establishes that anti-CGRP mAbs provide durable effectiveness and high adherence in difficult-to-treat populations. The data confirm a favorable cardiovascular safety profile, supporting their role as a cornerstone of modern migraine prevention.
References
Mascarella, D., Andrini, G., Baraldi, C., et al. (2024). Blood pressure monitoring in elderly migraineurs starting an anti-CGRP monoclonal antibody: A real-world prospective study. Neurological Sciences, 45, 5365–5373. https://doi.org/10.1007/s10072-024-07567-9
Cullum, C. K., Do, T. P., Ashina, M., et al. (2022). Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: A 52-week, single-center, prospective, observational study. The Journal of Headache and Pain, 23, 61. https://doi.org/10.1186/s10194-022-01433-9
Roongrojwittayakul, S., Anukoolwittaya, P., Hiransuthikul, A., et al. (2025). CGRP-targeted therapy fulfilling the treatment gap in medication-underuse setting: A retrospective cohort study at a tertiary headache center in Thailand, a lower-middle-income country. The Journal of Headache and Pain, 26, 224. https://doi.org/10.1186/s10194-025-02160-7
Triller, P., Blessing, V. N., Overeem, L. H., et al. (2024). Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study. Cephalalgia, 44, 03331024241288875. https://doi.org/10.1177/03331024241288875
Vernieri, F., Altamura, C., Brunelli, N., et al. (2021). Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: A multicenter prospective cohort study (the GARLIT study). The Journal of Headache and Pain, 22, 35. https://doi.org/10.1186/s10194-021-01247-1
Ashina, M., Mitsikostas, D. D., Amin, F. M., et al. (2025). Long-term real-world effectiveness and safety of fremanezumab in 1140 patients with migraine and at least 6 months of treatment: Third interim analysis of the pan-European PEARL study. Neurological Sciences, 46, 6907–6921. https://doi.org/10.1007/s10072-025-08484-1
Silvestro, M., Orologio, I., Sozio, P., et al. (2025). No additional benefit with detoxification strategies: A real world experience in 200 patients with chronic migraine and either simple or complex MOH treated with CGRP monoclonal antibodies. Cephalalgia, 45, 6. https://doi.org/10.1177/03331024251329808
Barbanti, P., Aurilia, C., Egeo, G., et al. (2025). A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II). Journal of Neurology, 272, 382. https://doi.org/10.1007/s00415-025-13095-z
Vernieri, F., Ambrosini, A., Bartolini, M., et al. (2025). The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectiveness. Neurological Sciences, 46, 6895–6905. https://doi.org/10.1007/s10072-025-08504-0
Ashina, M., Tassorelli, C., Kokturk, P., et al. (2025). Addressing unmet needs in migraine: Real-world fremanezumab effectiveness in participants of the PEARL study with at least three prior preventive treatment failures. Cephalalgia, 45, 12. https://doi.org/10.1177/03331024251395029
Imai, S., Ihara, K., Takahashi, N., et al. (2026). A 12-month observational study on the safety, efficacy on migraine-associated symptoms and satisfaction of CGRP monoclonal antibodies in Japanese patients with migraine. Journal of the Neurological Sciences, 481, 125751. https://doi.org/10.1016/j.jns.2026.125751
Dodick, D. W., Tepper, S. J., Ailani, J., et al. (2025). Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database-based observational cohort study. Headache, 65, 919–932. https://doi.org/10.1111/head.14912
Vaghi, G., Corrado, M., Pocora, M. M., et al. (2025). Real world effectiveness of anti-CGRP monoclonal antibodies over three consecutive one-year treatment cycles: An intention-to-treat analysis. Cephalalgia, 45, 8. https://doi.org/10.1177/03331024251353421
Barbanti, P., Aurilia, C., Torelli, P., et al. (2025). Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: The prospective, multicenter I-GRAINE study. Journal of Neurology, 272, 170. https://doi.org/10.1007/s00415-025-12911-w
Muñoz-Vendrell, A., Campoy, S., Caronna, E., et al. (2023). Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: A real-life multicentre analysis of 162 patients. The Journal of Headache and Pain, 24, 63. https://doi.org/10.1186/s10194-023-01585-2
Belvís, R., Irimia, P., Pozo-Rosich, P., et al. (2021). MAB-MIG: Registry of the Spanish Neurological Society of erenumab for migraine prevention. The Journal of Headache and Pain, 22, 74. https://doi.org/10.1186/s10194-021-01267-x
Lanteri-Minet, M., Fabre, R., Martin, C., et al. (2023). One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: Results of the French FHU INOVPAIN registry study. The Journal of Headache and Pain, 24, 152. https://doi.org/10.1186/s10194-023-01680-4
Andreou, A. P., Hill, B., Al-Rawi, R., et al. (2025). A prospective real-world analysis of intravenous eptinezumab in migraine management: The first UK experience. The Journal of Headache and Pain, 26, 235. https://doi.org/10.1186/s10194-025-02180-3
Lusk, J. B., Wilson, L. E., Moore, C., et al. (2026). Calcitonin gene–related peptide inhibitors and cardiovascular events in patients with migraine. Neurology, 106, e214479. https://doi.org/10.1212/WNL.0000000000214479
Yang, S., Orlova, Y., Park, H., et al. (2025). Cardiovascular safety of anti-CGRP monoclonal antibodies in older adults or adults with disability with migraine. JAMA Neurology, 82, 132–141. https://doi.org/10.1001/jamaneurol.2024.4537
Moura, C. S., Randall, J. R., Klarenbach, S., et al. (2026). Persistence, switching, and healthcare use after initiating calcitonin gene-related peptide inhibitors: A real-world assessment. The Journal of Headache and Pain, 27, 19. https://doi.org/10.1186/s10194-025-02167-0
Gunasekera, L., Cheng, S., Foster, E., et al. (2026). A retrospective audit of the real-world safety and effectiveness profile of eptinezumab for treatment-resistant chronic migraine in Australia. Headache, 66, 108–117. https://doi.org/10.1111/head.70015
Jaimes, A., Gómez, A., Pajares, O., et al. (2025). Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study. Headache, 65, 619–630. https://doi.org/10.1111/head.14865
Scheffler, A., Basten, J., Menzel, L., et al. (2024). Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache: A retrospective real-world analysis. The Journal of Headache and Pain, 25, 109. https://doi.org/10.1186/s10194-024-01813-3
Tepper, S. J., Dodick, D. W., Lanteri-Minet, M., et al. (2025). Efficacy and safety of erenumab in adults with medication overuse headache: Final results from a phase 4 randomized placebo-controlled study. European Journal of Neurology, 32, e70328. https://doi.org/10.1111/ene.70328
Pensato, U., Ornello, R., Rosignoli, C., et al. (2025). Longitudinal assessment of migraine burden in resistant and refractory migraine: Data from the prospective REFINE study. The Journal of Headache and Pain, 26, 184. https://doi.org/10.1186/s10194-025-02126-9
Andreou, A. P., Fuccaro, M., Hill, B., et al. (2022). Two-year effectiveness of erenumab in resistant chronic migraine: A prospective real-world analysis. The Journal of Headache and Pain, 23, 139. https://doi.org/10.1186/s10194-022-01507-8
van Veelen, N., van der Arend, B. W. H., Hiele, E., et al. (2025). Switching from ligand to receptor anti-calcitonin gene-related peptide (CGRP) antibodies or vice versa in non-responders: A controlled cohort study. European Journal of Neurology, 32, e16542. https://doi.org/10.1111/ene.16542
Lambru, G., Caponnetto, V., Hill, B., et al. (2023). Long-term effect of switching from an anti-CGRP receptor to an anti-CGRP ligand antibody in treatment-refractory chronic migraine: A prospective real-world analysis. Neurotherapeutics, 20, 1284–1293. https://doi.org/10.1007/s13311-023-01394-0
Muñoz-Vendrell, A., Campoy-Díaz, S., Díaz-Corta, P., et al. (2026). False nonresponders to anti-calcitonin gene-related peptide monoclonal antibodies: A real-world analysis beyond migraine frequency reduction. Headache, 66, 172–182. https://doi.org/10.1111/head.70012
Argoff, C., Herzog, S. P., Smith, R. M., et al. (2024). Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study. The Journal of Headache and Pain, 25, 65. https://doi.org/10.1186/s10194-024-01764-9
Iannone, L. F., Fattori, D., Benemei, S., et al. (2022). Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs, 36, 191–202. https://doi.org/10.1007/s40263-021-00893-y
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dawid Studziński, Marcin Schulz, Karolina Osińska, Agnieszk Morawa, Anna Kołcz, Michał Kulczak, Konrad Turczynowski, Kamil Turczynowski, Grzegorz Machelski, Jan Gajewski
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
